ULTRAVIST 150 Drug Patent Profile
✉ Email this page to a colleague
When do Ultravist 150 patents expire, and what generic alternatives are available?
Ultravist 150 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in ULTRAVIST 150 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ULTRAVIST 150?
- What are the global sales for ULTRAVIST 150?
- What is Average Wholesale Price for ULTRAVIST 150?
Summary for ULTRAVIST 150
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 11 |
Patent Applications: | 2,426 |
DailyMed Link: | ULTRAVIST 150 at DailyMed |
Recent Clinical Trials for ULTRAVIST 150
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Guerbet/Liebel-Flarsheim | Phase 4 |
Duke Clinical Research Institute | Phase 4 |
GE Healthcare | Phase 4 |
Pharmacology for ULTRAVIST 150
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for ULTRAVIST 150
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ULTRAVIST 150 | iopromide | INJECTABLE;INJECTION | 020220-004 | May 10, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ULTRAVIST 150
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | ULTRAVIST 150 | iopromide | INJECTABLE;INJECTION | 020220-004 | May 10, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ULTRAVIST 150
See the table below for patents covering ULTRAVIST 150 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 489337 | ⤷ Sign Up | |
Spain | 8107165 | ⤷ Sign Up | |
Portugal | 70915 | ⤷ Sign Up | |
Ireland | 800467 | ⤷ Sign Up | |
Japan | S55153755 | TRIIODOISOPHTHALIC ACID DIAMIDE DERIVATIVE* ITS MANUFACTURE AND X RAY CONTRAST AGENT CONTAINING IT | ⤷ Sign Up |
Norway | 148884 | ⤷ Sign Up | |
Egypt | 14530 | NON-IONIC X-RAY CONTRAST AGENTS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |